TAYMI RIVAL CASTILLO: Open Payments
NPI 1801465885 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,214 in 55 payments from 14 companies in 2025. Trend: 2023 $472 · 2024 $686 · 2025 $1,214
Food & beverage: $1,214
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 12 | $304 |
| GlaxoSmithKline, LLC. | 7 | $145 |
| AstraZeneca Pharmaceuticals LP | 3 | $145 |
| Novartis Pharmaceuticals Corporation | 6 | $114 |
| Lilly USA, LLC | 5 | $114 |
| ABBVIE INC. | 4 | $70 |
| Phathom Pharmaceuticals, Inc. | 5 | $68 |
| Novo Nordisk Inc | 3 | $56 |
| Merck Sharp & Dohme LLC | 2 | $48 |
| Amgen Inc. | 2 | $40 |
Products named: GEMTESA, TRELEGY ELLIPTA, LEQVIO, FARXIGA, MOUNJARO, VOQUEZNA, LINZESS, VERQUVO.
Industry payments across FL — which companies pay providers there.
